{"id":15590,"date":"2012-10-16T02:30:00","date_gmt":"2012-10-16T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/nello-martini-cavalcare-onda-dei-biosimilari\/"},"modified":"2012-10-16T02:30:00","modified_gmt":"2012-10-16T00:30:00","slug":"nello-martini-cavalcare-onda-dei-biosimilari","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/nello-martini-cavalcare-onda-dei-biosimilari\/","title":{"rendered":"Nello Martini: riding the wave of biosimilars"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">After the season of generics, destined to end within 5 years, it will be necessary to ride the &#039;wave&#039; of biosimilars to obtain the savings necessary to guarantee access to innovative, high-cost drugs. This was underlined by the president of the National Academy of Medicine, Nello Martini, speaking of how to combine economic sustainability and innovation in his speech at the XXXIII congress of Sifo, the Italian Society of Hospital Pharmacy in Bari. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">On generic drugs in Italy there are still &quot;trails of controversy but it is not possible for the NHS to finance innovation if after 10 years of patent duration a competitive market is not created which triggers a process of generalized price reduction. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">In 2012-13, with the expiry of the patent coverage on 13 active ingredients in the first year and 11 in the second, 536 million euros will be freed up. Important resources that should be used to ensure the reimbursement of innovative medicines&quot;. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">In the two-year period 2010-11, 64 new medicines were eligible for reimbursement by AIFA, half of which were for hospital use, for a cost of 257 million euro. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">From 2017, &quot;all chemical drugs will lose their patent, so no new generics will enter the market&quot;. It will then be time to ride the &#039;wave&#039; of biosimilars.<\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 10pt\"><i><span style=\"line-height: 115%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; color: #212120; font-size: 9pt; mso-bidi-font-weight: bold\">Adelisa Maio \u2013 October 16, 2012 \u2013 PharmaKronos<\/p>\n<p><\/span><\/i><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 10pt\"><b><span style=\"line-height: 115%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; color: #c00000; font-size: 18pt; mso-bidi-font-style: italic\">Italy, sixth market<\/p>\n<p><\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">Italy, with 24.5 billion in 2011, is confirmed as the third largest pharmaceutical market in Europe and the sixth in the world, but drops to 24th place for investments in research and development. This is the picture traced by the president of the ACC<\/p>","protected":false},"excerpt":{"rendered":"<p>Dopo la stagione dei generici, destinata a concludersi nel giro di 5 anni, sar&agrave; necessario cavalcare &#8216;l&#8217;onda&#8217; dei biosimilari per ottenere i risparmi necessari a garantire l&rsquo;accesso ai farmaci innovativi, ad alto costo. Lo ha sottolineato il presidente dell&rsquo;Accademia nazionale di medicina, Nello Martini, parlando di come coniugare sostenibilit&agrave; economica e innovazione nel suo intervento &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15590"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}